N° 008 · The Directory

Cerebrolysin

A complex of low-molecular-weight peptides derived from porcine brain. Approved in 50+ countries, not in the US.

A-Tier Cognitive Not FDA-approved

For: Stroke, TBI and cognitive recovery
Form: IV infusion (clinically administered)
Dose: 10-30 mL / day (IV)
Cycle: 10-21 days, repeat every 3-6 months
Safety: Avoid with severe kidney failure or epilepsy
Legal: Approved abroad; not FDA-approved

Bottom line: A brain peptide mix approved in 50+ countries for stroke and cognitive decline. Strong evidence; hard to source legally in the US.

Safety at a glance

Status: Approved in 50+ countries; not FDA-approved in the US.
Evidence: Large international trials; approved in 50+ countries, not FDA.
Do not use if: you have a seizure or epilepsy history, or significant kidney impairment.
Not medical advice - decide this with a licensed physician.

What it does - plain English

Cerebrolysin is a mixture of small peptides and amino acids extracted from pig brain tissue. It is not a single peptide but a defined extract, manufactured by EVER Pharma in Austria since the 1970s. Researchers use it for neuroprotection (protecting brain cells from damage during stroke or injury) and as a treatment adjunct for vascular dementia, Alzheimer's disease, and traumatic brain injury.

The mechanism is thought to mimic naturally-occurring neurotrophic factors - proteins your brain makes to keep neurons healthy and growing. Think of it as delivering the signals your brain sends to repair and maintain itself, from the outside.

Approved as a pharmaceutical in 50+ countries across Europe, Asia, and Latin America. Not approved by the FDA in the United States.

What people use it for

An A-tier neuro-recovery infusion, given clinically. Where it is used:

See the full Cerebrolysin dosing protocol ->

Status

A-tier internationally, B-tier US. The international evidence base is unusual for a peptide product: actual phase-3 trials, post-marketing surveillance over decades, and clinical use in stroke and cognitive-decline indications across multiple countries.

The US absence is a regulatory artifact, not a science problem. If you are researching cognitive peptides with the strongest evidence base, this is where the real data lives. The catch: sourcing it cleanly in the US is hard.

Legal status

Not FDA-approved in the United States. Approved as a prescription medication in Austria, Germany, China, Russia, Mexico, India, and 40+ other countries.

US patients sometimes obtain it via two routes, neither clean:

International pharmacy import - some patients obtain prescriptions from doctors abroad and import for personal use. Legality varies by state and federal posture. This is a gray zone, not a clear path.
Research peptide vendors - products sold under "Cerebrolysin" naming may not be the EVER Pharma branded extract. May not be authentic. Consumer protection: none.

The branded EVER Pharma product is what the trials use. Generics and "research grade" alternatives may not match.

Where to source

Two complicated paths. Neither is as clean as buying a compounding-pharmacy BPC-157.

International pharmacy import - some US patients obtain prescriptions from doctors abroad and import for personal use. Legality varies by state. One path, many variables.
Research peptide vendors - the products sold under "Cerebrolysin" naming may not be the EVER Pharma branded extract. Ask hard questions about sourcing and ingredient provenance. The COA standard here is "is this actually Cerebrolysin or a similar-but-different peptide blend."

A single-source vendor with documented EVER Pharma supply chain is the gold standard. Everything else requires more skepticism than usual. Subscribe below for vendor reviews when we have them.

New to peptides? Start with the foundations ->

Two studies worth reading

Stroke recovery RCT

Muresanu et al., "Cerebrolysin and Recovery After Stroke (CARS-1)", Stroke

208 patients with acute ischemic stroke. Cerebrolysin plus standard rehab outperformed standard rehab alone on motor function recovery at 90 days. The trial that anchors stroke-recovery use cases internationally.

Vascular dementia review

Cui et al., "Cerebrolysin for vascular dementia", Cochrane Database of Systematic Reviews

Cochrane systematic review - the gold standard format for evidence synthesis. Found Cerebrolysin produces measurable improvements in cognition for people with vascular dementia, though magnitudes are modest. Worth reading for an honest assessment of effect sizes.

From the Editor

My take: Cerebrolysin is the cognitive peptide where the evidence is real, well-documented, and used clinically by neurologists outside the US. The frustrating part is that US regulatory absence forces patients into gray-zone sourcing for what is a pharmacist-dispensed prescription drug everywhere else. Worth knowing about. Harder to actually use cleanly.

What I'd tell my dad: if there has been a stroke, TBI, or vascular-dementia diagnosis, ask the neurologist if they have considered Cerebrolysin. If they say "not approved in the US," ask if they have international colleagues with experience prescribing it. This is a peptide where having a specialist physician matters more than sourcing.

What I'd skip: any vendor selling "Cerebrolysin" at suspiciously low prices, especially if they cannot explain whether the product is the EVER Pharma extract or a synthetic alternative. Authenticity is the problem here, not just purity.

Your next step

How to vet a source Find your fit · 2-min quiz

Last reviewed · 2026·05·04 · Status reviewed weekly